Physician profile
Danny Liang
NPI 1760518807
$198,723.52
in general payments reported to CMS, 2019-2025
53 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,149 · 2020: $46K · 2021: $53K · 2022: $43K · 2023: $48K · 2024: $7,780.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $48K · Consulting Fee: $7,000 · Food and Beverage: $690.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $48,156.35 |
| Consulting Fee | $7,000.00 |
| Food and Beverage | $689.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Altus Partners. LLC | $185,845.82 | 2020-2024 | Silverstone Titanium Interbody Fusion System, Suzuka Interbody Fusion System |
| Cerapedics INC. | $6,533.63 | 2021 | |
| Baxter Healthcare | $2,185.73 | 2019-2021 | |
| Si-Bone, INC. | $1,425.04 | 2019-2024 | |
| Centinel Spine, LLC | $882.54 | 2021-2022 | |
| Boston Scientific Corporation | $180.51 | 2019 | |
| Globus Medical, INC. | $119.43 | 2019 | |
| Carl Zeiss Meditec USA, INC. | $103.85 | 2022 | |
| Ucb, INC. | $93.93 | 2019-2024 | Briviact |
| Alexion Pharmaceuticals, INC. | $83.70 | 2019-2021 | |
| Csl Behring | $68.84 | 2019-2024 | Kcentra |
| Eisai INC. | $61.41 | 2020-2023 | |
| Neurelis, INC. | $59.34 | 2023-2024 | Valtoco |
| Lilly USA, LLC | $53.68 | 2019-2024 | Amyvid, Emgality, Reyvow |
| Arbor Pharmaceuticals, INC. | $50.35 | 2019-2021 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danny Liang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.